BASTA JAMES
SEC CIK 1792726 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| NTLA | Intellia Therapeutics, Inc. | EVP, GC | 156.8K | — | $499.7K | 13 | 2022-03-01 | 2026-03-02 |
Most active insiders at NTLA, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | LEONARD JOHN M | Pres, CEO, Dir | — | $1.44M |
| 2 | Cohen Fred E | Dir | $1.40M | — |
| 3 | Dulac Edward J III | EVP, CFO | — | $234.2K |
| 4 | BASTA JAMES | EVP, GC | — | $112.4K |
| 5 | Lebwohl David | EVP, Chief Medical Off | — | $109.6K |
| 6 | Dube Michael P | VP, CAO | — | $104.4K |
| 7 | Clark Eliana | EVP, Chief Technical Off | — | $96.0K |
| 8 | Schultes Birgit C | EVP, CSO | — | $78.9K |
| 9 | Bhanji Muna | Dir | — | — |
| 10 | Keresty Georgia | Dir | — | — |
Transactions 13
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-03-03 | 2026-03-01 | NTLA | Intellia Therapeutics, Inc. | BASTA JAMES | EVP, GC | A - Grant | $0.00 | +46.1K | 158.0K | +41% | $0 |
| D | 2026-03-03 | 2026-03-02 | NTLA | Intellia Therapeutics, Inc. | BASTA JAMES | EVP, GC | S - Sale | $13.78 | -1,211 | 156.8K | -0.8% | -$16.7K |
| 2026-01-07 | 2026-01-05 | NTLA | Intellia Therapeutics, Inc. | BASTA JAMES | EVP, GC | S - Sale | $9.21 | -10.4K | 101.5K | -9% | -$95.8K | |
| D | 2025-03-04 | 2025-03-04 | NTLA | Intellia Therapeutics, Inc. | BASTA JAMES | EVP, GC | S - Sale | $8.99 | -2,572 | 111.9K | -2% | -$23.1K |
| D | 2025-03-04 | 2025-03-01 | NTLA | Intellia Therapeutics, Inc. | BASTA JAMES | EVP, GC | A - Grant | $0.00 | +40.0K | 114.5K | +54% | $0 |
| 2025-01-07 | 2025-01-03 | NTLA | Intellia Therapeutics, Inc. | BASTA JAMES | EVP, GC | S - Sale | $12.18 | -7,074 | 74.5K | -9% | -$86.2K | |
| D | 2024-03-05 | 2024-03-01 | NTLA | Intellia Therapeutics, Inc. | BASTA JAMES | EVP, GC | A - Grant | $0.00 | +32.4K | 83.9K | +63% | $0 |
| D | 2024-03-05 | 2024-03-04 | NTLA | Intellia Therapeutics, Inc. | BASTA JAMES | EVP, GC | S - Sale | $32.99 | -2,297 | 81.6K | -3% | -$75.8K |
| 2024-01-05 | 2024-01-03 | NTLA | Intellia Therapeutics, Inc. | BASTA JAMES | EVP, GC | S - Sale | $29.46 | -3,805 | 51.5K | -7% | -$112.1K | |
| DM | 2023-03-03 | 2023-03-01 | NTLA | Intellia Therapeutics, Inc. | BASTA JAMES | EVP, GC | A - Grant | $0.00 | +36.8K | 44.1K | +505% | $0 |
| D | 2023-03-03 | 2023-03-02 | NTLA | Intellia Therapeutics, Inc. | BASTA JAMES | EVP, GC | S - Sale | $43.88 | -1,088 | 55.3K | -2% | -$47.7K |
| 2023-01-06 | 2023-01-04 | NTLA | Intellia Therapeutics, Inc. | BASTA JAMES | EVP, GC | S - Sale | $37.21 | -1,138 | 19.6K | -5% | -$42.3K | |
| DM | 2022-03-03 | 2022-03-01 | NTLA | Intellia Therapeutics, Inc. | BASTA JAMES | EVP, GC | A - Grant | $0.00 | +20.7K | 20.7K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations